Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCI020302
- Development stage
- Preclinical
- Lead developer
- Pattern Computer
- Modality
- Small Molecules
01
Overview
**PCI020302** is Pattern Computer's preclinical, AI-discovered combination therapy for **triple-negative breast cancer**. Pattern's patent portfolio identifies the combination as **idelalisib + defactinib**, intended to produce synergistic antitumor activity. Idelalisib inhibits phosphatidylinositol 3-kinase delta, while defactinib inhibits focal adhesion kinase and protein tyrosine kinase 2 beta. The candidate was discovered using Pattern Computer's PatternDE platform and has reported activity in preclinical animal models. ([patterncomputer.com](https://www.patterncomputer.com/pattern-expands-global-patent-protection-for-pci020302-across-u-s-mexico-europe-and-australia/))
- Other names
- idelalisib + defactinib
02
Targets
FAK (Focal adhesion kinase)PTK2BPIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on PCI020302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCI020302.